Onclive Team

Articles

Mastering New Advances in Hematologic Malignancies in Milwaukee

August 21st 2019

We traveled to Milwaukee, Wisconsin, for a State of the Science Summit™ on Hematologic Malignancies, which featured insights from the faculty from the Medical College of Wisconsin.

Talking Tumors: Leveraging Immunotherapy in Nonsquamous NSCLC

August 14th 2019

Stephen V. Liu, MD, of Medstar Georgetown University Medical Center, and Konstantinos Arnaoutakis, MD, of Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences, discuss the results of a Twitter poll regarding the use of single-agent immunotherapy versus combination chemotherapy and immunotherapy in a patient with nonsquamous non–small cell lung cancer and to shed light on the data that support each intended treatment choice.

City of Hope Scientist Receives $9.28 Million for CAR T Cell Immunotherapy Clinical Trial for Patients With HER2-Positive Breast Cancer That Has Spread to the Brain

August 14th 2019

Saul Priceman, PhD, City of Hope assistant professor in the Department of Hematology & Hematopoietic Cell Transplantation, and his research team have received a $9.28 million award from the California Institute for Regenerative Medicine to support a chimeric antigen receptor T cell phase 1 clinical trial for the treatment of women with HER2-positive breast cancer that has spread to the brain.

Relapsed Myeloma: With Great Options Comes Great Responsibility

August 9th 2019

Noopur Raje, MD, highlights the multitude of available and emerging options in relapsed myeloma, as well as the key factors for treatment selection in this heterogeneous population.

Newfound Understandings of Neuroendocrine Treatment in Kentucky

August 7th 2019

We traveled to Lexington, Kentucky, for a State of the Science Summit™ on Neuroendocrine Tumors, which featured insights from the faculty from University of Kentucky Markey Cancer Center.

Pelotonia Institute for Immuno-Oncology Launched at Ohio State with $102,265,000 Investment

August 2nd 2019

The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute announced formation of the Pelotonia Institute for Immuno-Oncology, a comprehensive bench-to-bedside research initiative focused on harnessing the body’s immune system to fight cancer at all levels—from prevention to treatment and survivorship.

Siteman Cancer Center Awarded $7.8 Million to Expand Clinical Trials Access

August 2nd 2019

Physicians at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis have been awarded a $7.8 million grant from the National Cancer Institute to play a leading role in designing, conducting and enrolling patients in clinical trials through the NCI

Perusing Breakthroughs in Breast Cancer in Pasadena

July 31st 2019

We traveled to Pasadena, California, for a State of the Science Summit™ on Breast Cancer, which featured insights from the faculty from City of Hope.

City of Hope Named 11th Best Cancer Hospital in the Nation by U.S. News & World Report

July 30th 2019

With its long-standing commitment to patients, the designation makes City of Hope the highest ranked cancer hospital in the West.

Sylvester Comprehensive Cancer Centerat the University of Miami Earns Prestigious National Cancer Institute Designation

July 30th 2019

Sylvester Comprehensive Cancer Center, part of the University of Miami Leonard M. Miller School of Medicine, has received the prestigious NCI designation from the National Cancer Institute.

Pelotonia Institute for Immuno-Oncology Launched at Ohio State with $102,265,000 Investment

July 29th 2019

Financial pledge from Pelotonia represents one of the largest gifts ever to The Ohio State University and honors the 2,265 riders who participated in the inaugural ride in 2009.

City of Hope Study Finds a Novel Mechanism of Action for Natural Killer Cells in Checkpoint Inhibitor Therapy for Cancer

July 29th 2019

PD-L1–positive natural killer cells may prove to be another important immune effector cell for checkpoint inhibitor-based cancer immunotherapy.

Patrick I. Borgen, MD: From the Wild West of Breast Cancer Research to Chasing Cure

July 24th 2019

Patrick I. Borgen, MD, of Maimonides Medical Center, shares his live-by mottos as a breast cancer surgeon, a patient who defined his career, and what fuels his passion to fight breast cancer and remove opioid use after surgery.

UT Southwestern Researchers Find Evidence a Cancer Drug May Be Extended to Many More Patients

July 24th 2019

A new molecular mechanism discovered by UT Southwestern researchers indicates that drugs currently used to treat less than 10 percent of breast cancer patients could have broader effectiveness in treating all cancers where the drugs are used, including ovarian and prostate cancers.

Statistics Show Increase in US Cancer Survivors

July 20th 2019

The growth and aging of the population combined with advances in the early detection and treatment of cancer have resulted in a growing population of survivors across the nation, according to a study from the American Cancer Society and the National Cancer Institute.

Navigating New Developments in NSCLC in Dallas

July 18th 2019

We traveled to Dallas, Texas, for a State of the Science Summit™ on Non–Small Cell Lung Cancer, which featured insights from Baylor Scott and White Health System faculty.

Practical Perspectives on the Diagnosis and Treatment of Hairy Cell Leukemia

July 13th 2019

Gary J. Schiller, MD, discusses the challenges with treating patients with hairy cell leukemia and some emerging therapies that could impact clinical practice.

Tapping Into Great Progress Made in GI Cancers in Tampa

July 13th 2019

We traveled to Tampa, Florida, for a State of the Science Summit™ on Gastrointestinal Malignancies, which featured insights from the faculty from Moffitt Cancer Center and Mayo Clinic.

Advances in the Treatment of Relapsed or Refractory Hairy Cell Leukemia

July 12th 2019

After decades of quiescence, the therapeutic landscape of hairy cell leukemia is undergoing rapid evolution.

Hairy Cell Leukemia: A Review of Epidemiology and Disease Presentation

July 11th 2019

Despite the significant progress that has been made regarding the incidence, risk factors, and symptoms of hairy cell leukemia, diagnosis remains a challenge, due in part to the low incidence of the disease.